Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

INCB028050

Known as: INCB 028050 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

baricitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of… Expand
2013
2013
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
Background LY3009104 (LY) is a novel, oral inhibitor of the JAK1/JAK2 signalling pathway known to be important in the… Expand
2013
2013
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds
Janus kinase (JAK) inhibitors have been developed as anti‐inflammatory agents and have demonstrated clinical efficacy in… Expand
Review
2013
Review
2013
SP0169 JAK inhibition in patients with rheumatoid arthritis
The Janus Kinase (JAK) group of tyrosine kinases are intracellular signaling molecules which become phosphorylated upon… Expand
2012
2012
F1000Prime recommendation of A Randomized Dose-Ranging, Placebo-Controlled Study of INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects with Active Rheumatoid Arthritis.
 
Highly Cited
2010
Highly Cited
2010
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
2010
2010
Selective Inhibition of JAK 1 and JAK 2 Is Efficacious in Rodent Models of Arthritis : Preclinical Characterization of INCB 028050
 
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
2010
2010
Preclinical Characterization of INCB 028050 Efficacious in Rodent Models of Arthritis : Selective Inhibition of JAK 1 and JAK 2 Is
 
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Review
2010
Review
2010
Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
  • H. Kato, D. Fox
  • Clinical and translational science
  • 2010
    • Corpus ID: 2058066
Th17 cells play crucial roles not only in host defense but also in many human autoimmune diseases and corresponding animal models… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE